TECX earnings analysis
What we found in TECX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Tectonic Therapeutic, Inc. (TECX) reported significant financial losses for Q1 2026, with a net loss increasing to $25.2 million from $15.9 million in Q1 2025, demonstrating a substantial 59% year-over-year increase. Operating expenses rose sharply, driven primarily by research and development costs related to ongoing clinical trials. The company's cash position remains healthy at $236.9 million; however, uncertainties around effective capital management and compliance obligations present ongoing risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Increased Net Loss: $25M Q1 2026
- Net loss for Q1 2026 was $(25.2M), up from $(15.9M) in Q1 2025, marking a 59% increase year-over-year.
- R&D Expenses Surge: $20.9M
- Research and development expenses surged to $20.9 million in Q1 2026, up from $13.0 million in Q1 2025, reflecting increased costs for ongoing clinical trials.
- Operating Cash Flow: $(18.4M)
- Operating cash flow for Q1 2026 was $(18.4M), compared to $(13.1M) in Q1 2025.
- Cash Reserves: $236.9M Maintained
- Cash and cash equivalents stood at $236.9 million as of March 31, 2026, down from $254.9 million at the end of 2025.
- Increase in Outstanding Shares
- Outstanding shares increased from 18,738,249 at end of 2025 to 18,830,436 at March 31, 2026.
- High Dependency on Third-Party Manufacturers
- As of Q1 2026, reliance on WuXi Biologics for manufacturing TX45 raises risks of supply chain disruptions.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Significant Operating Losses
- Q1 2026 net loss of $(25.2M) raises concerns over long-term sustainability given continued operational deficits.
- Regulatory Risks Related to Compliance
- Compliance with evolving healthcare and data protection regulations may lead to increased costs and operational disruption.
- Reliance on Third-Party Suppliers
- Dependency on third-party manufacturers, particularly in politically sensitive regions, may jeopardize supply chain integrity if disruptions occur.
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
What came before.
- 10-K · February 26, 2026
- Tectonic Therapeutic positions itself as a GPCR-focused, clinical-stage biologics company leveraging its proprietary GEODe™ discovery platform to develop GPCR-targeted proteins and antibodies. The company’s lead asset…
- 10-Q · November 6, 2025
- Tectonic Therapeutic reported a Q3 2025 loss of $19.0 million ($-1.02 EPS) compared to a loss of $17.7 million ($-1.20 EPS) in Q3 2024. The company continues to experience significant cash burn, reporting net cash used…
- 10-Q · August 7, 2025
- Tectonic Therapeutic reported a Q2 net loss of $19.98 million (‑$1.07 per share) vs. a loss of $12.67 million in Q2 2024, driven by higher R&D and G&A spend. Liquidity materially improved after a private placement that…
- 10-Q · August 14, 2024
- Tectonic completed a reverse recapitalization/merger on June 20, 2024 and raised material cash from a Subscription Agreement and the Merger, leaving cash and equivalents of $185,124 (in thousands) as of June 30, 2024.…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TECX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever